Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates

Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

Jien Wei Liu, Wen Chien Ko, Cheng Hua Huang, Chun Hsing Liao, Chin Te Lu, Yin Ching Chuang, Shih Ming Tsao, Yao Shen Chen, Yung Ching Liu, Wei Yu Chen, Tsrang Neng Jang, Hsiu Chen Lin, Chih Ming Chen, Zhi Yuan Shi, Sung Ching Pan, Jia Ling Yang, Hsiang Chi Kung, Chun Eng Liu, Yu Jen Cheng, Yen Hsu Chen & 9 others Po Liang Lu, Wu Sun, Lih Shinn Wang, Kwok Woon Yu, Ping Cherng Chiang, Ming Hsun Lee, Chun Ming Lee, Gwo Jong Hsu, Po Ren Hsueh

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were

Original languageEnglish
Pages (from-to)1414-1417
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Acinetobacter baumannii
Taiwan
Klebsiella pneumoniae
Methicillin-Resistant Staphylococcus aureus
United States Food and Drug Administration
Escherichia coli
Bacteria
Enterococcus faecium
Pharmaceutical Preparations
tigecycline
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates : Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. / Liu, Jien Wei; Ko, Wen Chien; Huang, Cheng Hua; Liao, Chun Hsing; Lu, Chin Te; Chuang, Yin Ching; Tsao, Shih Ming; Chen, Yao Shen; Liu, Yung Ching; Chen, Wei Yu; Jang, Tsrang Neng; Lin, Hsiu Chen; Chen, Chih Ming; Shi, Zhi Yuan; Pan, Sung Ching; Yang, Jia Ling; Kung, Hsiang Chi; Liu, Chun Eng; Cheng, Yu Jen; Chen, Yen Hsu; Lu, Po Liang; Sun, Wu; Wang, Lih Shinn; Yu, Kwok Woon; Chiang, Ping Cherng; Lee, Ming Hsun; Lee, Chun Ming; Hsu, Gwo Jong; Hsueh, Po Ren.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 3, 03.2012, p. 1414-1417.

Research output: Contribution to journalArticle

Liu, JW, Ko, WC, Huang, CH, Liao, CH, Lu, CT, Chuang, YC, Tsao, SM, Chen, YS, Liu, YC, Chen, WY, Jang, TN, Lin, HC, Chen, CM, Shi, ZY, Pan, SC, Yang, JL, Kung, HC, Liu, CE, Cheng, YJ, Chen, YH, Lu, PL, Sun, W, Wang, LS, Yu, KW, Chiang, PC, Lee, MH, Lee, CM, Hsu, GJ & Hsueh, PR 2012, 'Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010', Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1414-1417. https://doi.org/10.1128/AAC.05879-11
Liu, Jien Wei ; Ko, Wen Chien ; Huang, Cheng Hua ; Liao, Chun Hsing ; Lu, Chin Te ; Chuang, Yin Ching ; Tsao, Shih Ming ; Chen, Yao Shen ; Liu, Yung Ching ; Chen, Wei Yu ; Jang, Tsrang Neng ; Lin, Hsiu Chen ; Chen, Chih Ming ; Shi, Zhi Yuan ; Pan, Sung Ching ; Yang, Jia Ling ; Kung, Hsiang Chi ; Liu, Chun Eng ; Cheng, Yu Jen ; Chen, Yen Hsu ; Lu, Po Liang ; Sun, Wu ; Wang, Lih Shinn ; Yu, Kwok Woon ; Chiang, Ping Cherng ; Lee, Ming Hsun ; Lee, Chun Ming ; Hsu, Gwo Jong ; Hsueh, Po Ren. / Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates : Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 3. pp. 1414-1417.
@article{246254597e964228a278b6afdd2d2cd0,
title = "Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010",
abstract = "The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4{\%} for ESBL-producing K. pneumoniae and 33.8{\%} for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6{\%}) for A. baumannii isolates. The total error rates between these two methods were",
author = "Liu, {Jien Wei} and Ko, {Wen Chien} and Huang, {Cheng Hua} and Liao, {Chun Hsing} and Lu, {Chin Te} and Chuang, {Yin Ching} and Tsao, {Shih Ming} and Chen, {Yao Shen} and Liu, {Yung Ching} and Chen, {Wei Yu} and Jang, {Tsrang Neng} and Lin, {Hsiu Chen} and Chen, {Chih Ming} and Shi, {Zhi Yuan} and Pan, {Sung Ching} and Yang, {Jia Ling} and Kung, {Hsiang Chi} and Liu, {Chun Eng} and Cheng, {Yu Jen} and Chen, {Yen Hsu} and Lu, {Po Liang} and Wu Sun and Wang, {Lih Shinn} and Yu, {Kwok Woon} and Chiang, {Ping Cherng} and Lee, {Ming Hsun} and Lee, {Chun Ming} and Hsu, {Gwo Jong} and Hsueh, {Po Ren}",
year = "2012",
month = "3",
doi = "10.1128/AAC.05879-11",
language = "English",
volume = "56",
pages = "1414--1417",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates

T2 - Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

AU - Liu, Jien Wei

AU - Ko, Wen Chien

AU - Huang, Cheng Hua

AU - Liao, Chun Hsing

AU - Lu, Chin Te

AU - Chuang, Yin Ching

AU - Tsao, Shih Ming

AU - Chen, Yao Shen

AU - Liu, Yung Ching

AU - Chen, Wei Yu

AU - Jang, Tsrang Neng

AU - Lin, Hsiu Chen

AU - Chen, Chih Ming

AU - Shi, Zhi Yuan

AU - Pan, Sung Ching

AU - Yang, Jia Ling

AU - Kung, Hsiang Chi

AU - Liu, Chun Eng

AU - Cheng, Yu Jen

AU - Chen, Yen Hsu

AU - Lu, Po Liang

AU - Sun, Wu

AU - Wang, Lih Shinn

AU - Yu, Kwok Woon

AU - Chiang, Ping Cherng

AU - Lee, Ming Hsun

AU - Lee, Chun Ming

AU - Hsu, Gwo Jong

AU - Hsueh, Po Ren

PY - 2012/3

Y1 - 2012/3

N2 - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were

AB - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were

UR - http://www.scopus.com/inward/record.url?scp=84863121492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863121492&partnerID=8YFLogxK

U2 - 10.1128/AAC.05879-11

DO - 10.1128/AAC.05879-11

M3 - Article

VL - 56

SP - 1414

EP - 1417

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -